Ipamorelin for postoperative ileus: a phase 3 study — VialBase Research
medium
- Ipamorelin accelerated GI recovery after abdominal surgery
- Reduced time to first bowel movement
- Demonstrated prokinetic effects independent of GH release
Summary
Clinical trial evaluating ipamorelin for postoperative ileus (POI) — the temporary cessation of bowel function after abdominal surgery. The study demonstrated that ipamorelin has prokinetic (gut motility) effects through ghrelin receptor activation, representing a therapeutic application distinct from GH release.
Key Findings
- Ipamorelin accelerated gastrointestinal recovery after abdominal surgery
- Reduced time to first bowel movement compared to placebo
- Prokinetic effects mediated through ghrelin receptor (GHS-R1a) in the GI tract
- GI motility effects independent of growth hormone release
- Well-tolerated in the postoperative setting
- Demonstrates ghrelin receptor agonism has effects beyond GH secretion
Methodology
Randomized, double-blind, placebo-controlled trial in 114 patients undergoing abdominal surgery. Ipamorelin administered intravenously post-surgery. Primary endpoint: time to first bowel movement. Secondary endpoints included time to tolerance of solid food and hospital discharge.
Limitations
- Specific to postoperative context — does not inform on chronic use
- Intravenous administration (not subcutaneous as used in peptide therapy)
- POI is an acute condition — different context from anti-aging/body composition use
- Phase 3 program was ultimately discontinued
- Does not assess GH-mediated benefits
Relevance to Content
Demonstrates that ipamorelin has FDA-investigated (though not approved) clinical applications. The GI motility angle is interesting for content about gut health benefits of ipamorelin. Also confirms the safety profile in a clinical trial setting. However, this is a different use case from the typical anti-aging/body composition application.
See Also
- Parent compound: Ipamorelin